# Filing Detail

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-099393
Filing Date
2026-03-10
Accepted
2026-03-10 07:48:55
Documents
59
Period of Report
2025-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-K | tennx-20251231.htm iXBRL | 10-K | 2696187
2 | EX-4.16 | tennx-ex4_16.htm | EX-4.16 | 40876
3 | EX-23.1 | tennx-ex23_1.htm | EX-23.1 | 3739
4 | EX-31.1 | tennx-ex31_1.htm | EX-31.1 | 15684
5 | EX-31.2 | tennx-ex31_2.htm | EX-31.2 | 17853
6 | EX-32.1 | tennx-ex32_1.htm | EX-32.1 | 9236
7 | EX-32.2 | tennx-ex32_2.htm | EX-32.2 | 8623
| Complete submission text file | 0001193125-26-099393.txt |  | 8279077

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
8 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | tennx-20251231.xsd | EX-101.SCH | 882295
61 | EXTRACTED XBRL INSTANCE DOCUMENT | tennx-20251231_htm.xml | XML | 1345633

Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-34600 | Film No.: 26737252
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)